$2.38
-0.02 (-0.83%)
Open$2.42
Previous Close$2.40
Day High$2.43
Day Low$2.28
52W High$4.11
52W Low$0.41
Volume—
Avg Volume581.7K
Market Cap147.11M
P/E Ratio—
EPS$-0.64
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+484.5% upside
Current
$2.38
$2.38
Target
$13.91
$13.91
$12.64
$13.91 avg
$18.47
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 7.04M | 7.06M | 6.30M |
| Net Income | 1.07M | 1.40M | 1.10M |
| Profit Margin | 15.2% | 19.8% | 17.5% |
| EBITDA | 1.93M | 2.06M | 1.69M |
| Free Cash Flow | 1.16M | 752.4K | 1.14M |
| Rev Growth | -2.7% | +19.8% | -1.2% |
| Debt/Equity | 1.45 | 1.09 | 1.43 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |